Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 3 matches for

The collective force of cancer research, outreach and care across the city of Oxford, translating discoveries into better care for cancer patients.

CRUK funding success to take LynchVax from an OCION Pump Prime award towards a clinical trial

Fewer than 12 months ago the ‘Oxford Cancer Immuno-Oncology Network’ (OCION) awarded £20,000 Pump Prime funding to a team led by Associate Professor David Church, who has now grown this pot over 27-times in funding from CRUK!

Oxford receives funding to develop a cancer prevention vaccine for Lynch syndrome

Cancer Research UK funds University of Oxford scientists to develop ‘LynchVax’, the UK’s first vaccine aiming to prevent cancer in people with Lynch syndrome who have a much higher risk of developing several types of cancer.

OCION Funding Scheme: In conversation with David Church and Luciana Gneo

The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardees, David Church and Luciana Gneo, to discuss what research the fund will enable them to carry out.